Research

  1. Our Sarcoma Research
  2. About Sarcoma Research
  3. Clinical Trials and Studies
  4. Sarcoma Research Grant Program
    1. ANZSA 2024 Sarcoma Research Grant
  5. Frequently Asked Questions
  6. Publications

Publications

Selected publications from ANZSA supported researchers. 

2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011

  • Ballinger ML et al. Heritable defects in telomere and mitotic function selectively predispose to sarcomas. Science. 2023 Jan 20;379(6629):253-260. doi: 10.1126/science.abj4784. Epub 2023 Jan 19. PMID: 36656928.

  • Gianferante DM, Moore A, Spector LG, Wheeler W, Yang T, Hubbard A, Gorlick R, Patiño-Garcia A, Lecanda F, Flanagan AM, Amary F, Andrulis IL, Wunder JS, Thomas DM, Ballinger ML, Serra M, Hattinger C, Demerath E, Johnson W, Birmann BM, De Vivo I, Giles G, Teras LR, Arslan A, Vermeulen R, Sample J, Freedman ND, Huang WY, Chanock SJ, Savage SA, Berndt SI, Mirabello L. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. Cancer Epidemiol. 2023 Aug 16:102432. doi: 10.1016/j.canep.2023.102432. Epub ahead of print. PMID: 37596165.

  • Klingberg, D., Bae, S., Zhou, D.D.X., Sim, H.W., Cai, R., Anazodo, A., Grimison, P., Lewis, C. and Lee, Y.C., 2023. Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma. Asia‐Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.13998

  • Ng JY, Warwick L, Craft P, Austen L, Ashford B, Gorddard N, Ballinger ML, Thomas DM, Blombery P, Tucker K, Polizzotto MN. Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature. Br J Haematol. 2023 Aug 22. doi: 10.1111/bjh.19059. Epub ahead of print. PMID: 37608704.

  • Zhou, D.D.X., Connolly, E.A., Mar, J., Lazarakis, S., Grimison, P.S., Connor, J., Gyorki, D.E. and Hong, A.M., 2023. A systematic review of the role of chemotherapy in retroperitoneal sarcoma by the Australia and New Zealand sarcoma association clinical practice guidelines working party. Cancer Treatment Reviews, p.102663.

  • Bae, S., Brnabic, A., Crowe, P., Carey‐Smith, R., Andelkovic, V., Singhal, N., Stalley, P., Yip, D., & Desai, J.. (2022). Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective. Asia-pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.13706

  • Connolly, E. A., Bhadri, V. A., Wake, J., Ingley, K. M., Lewin, J., Bae, S., Wong, D. D., Long, A. P., Pryor, D., Thompson, S. R., Strach, M. C., Grimison, P. S., Mahar, A., Bonar, F., Maclean, F., & Hong, A.. (2022). Systemic treatments and outcomes in CIC ‐rearranged Sarcoma: A national multi‐centre clinicopathological series and literature review. Cancer Medicine. https://doi.org/10.1002/cam4.4580

  • Hong AM, Lo H, Lawless A, Zhou D, Bae S, Phillips M, Maclean F, Desai J, Mar J, Lazarakis S, Pryor D, Thompson SR; Australia and New Zealand Sarcoma Association Guidelines Working Party. The benefit for radiotherapy at specialised sarcoma centres: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association. Radiother Oncol. 2022 Dec;177:158-162. doi: 10.1016/j.radonc.2022.10.037. Epub 2022 Nov 3. PMID: 36336110.

  • Strach MC, Grimison PS, Hong A, Boyle R, Stalley P, Karim R, Connolly EA, Bae S, Desai J, Crowe P, Singhal N, Bhadri VA. Mesenchymal chondrosarcoma: An Australian multi-centre cohort study. Cancer Med. 2022 May 23. doi: 10.1002/cam4.4849. Epub ahead of print. PMID: 35603739.

  • Sylvester DE, Chen Y, Grima N, Saletta F, Padhye B, Bennetts B, Wright D, Krivanek M, Graf N, Zhou L, Catchpoole D, Kirk J, Latchoumanin O, Qiao L, Ballinger M, Thomas D, Jamieson R, Dalla-Pozza L, Byrne JA. Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer. Genes Chromosomes Cancer. 2022 Feb;61(2):81-93. doi: 10.1002/gcc.23006. Epub 2021 Oct 30. PMID: 34687117.

  • Bagaria SP, Swallow C, Suraweera H, Raut CP, Fairweather M, Cananzi F, Quagliuolo V, Grignani G, Hompes D, Ford SJ, Nessim C, Apte S, Skoczylas J, Rutkowski P, Bonvalot S, Tzanis D, Gabriel E, Pennacchioli E, Albertsmeier M, Canter RJ, Pollock R, Grignol V, Cardona K, Gamboa AC, Novak M, Stoeckle E, Almquist M, Ahuja N, Klemen N, Van Houdt W, Gyorki D, Gangi A, Rastrelli M, van der Hage J, Schrage Y, Valeri S, Conti L, Spiegel MR, Li Z, Fiore M, Gronchi A. Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg Oncol. 2021 Oct;28(11):6882-6889. doi: 10.1245/s10434-021-09739-9. Epub 2021 Mar 19. Erratum in: Ann Surg Oncol. 2022 Mar 17;: PMID: 33740198.

  • Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB, Kramer B. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther. 2021 Apr;28(3-4):321-334. doi: 10.1038/s41417-020-00221-4. Epub 2020 Sep 1. PMID: 32873870; PMCID: PMC8057949.

  • Lu J, Wood D, Ingley E, Koks S, Wong D. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma. Mol Biol Rep. 2021 Apr;48(4):3637-3647. doi: 10.1007/s11033-021-06362-5. Epub 2021 Apr 24. PMID: 33893924.

  • Mahajan P, Casanova M, Ferrari A, Fordham A, Trahair T, Venkatramani R. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Probl Cancer. 2021 Aug;45(4):100768. doi: 10.1016/j.currproblcancer.2021.100768. Epub 2021 Jul 1. PMID: 34244015.

  • Omer N, Nicholls W, Ruegg B, Souza-Fonseca-Guimaraes F, Rossi GR. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma. Front Immunol. 2021 Nov 4;12:791206. doi: 10.3389/fimmu.2021.791206. PMID: 34804076; PMCID: PMC8600077.

  • Snow H, Mitchell C, Hendry S, McKinley M, Byrne D, Ngan S, Chander S, Chu J, Desai J, Bae S, Henderson M, Choong P, Gyorki D. Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy. J Surg Oncol. 2021 Jan;123(1):117-126. doi: 10.1002/jso.26261. Epub 2020 Oct 20. PMID: 33084061.

  • Vargas AC, Ardakani NM, Wong DD, Maclean FM, Kattampallil J, Boyle R, Santos L, Gill AJ. Chromosomal imbalances detected in NTRK-rearranged sarcomas by the use of comparative genomic hybridisation. Histopathology. 2021 Jun;78(7):932-942. doi: 10.1111/his.14295. Epub 2021 Apr 10. PMID: 33128780.

  • Vargas AC, Gray LA, White CL, Maclean FM, Grimison P, Ardakani NM, Bonar F, Algar EM, Cheah AL, Russell P, Mahar A, Gill AJ. Genome wide methylation profiling of selected matched soft tissue sarcomas identifies methylation changes in metastatic and recurrent disease. Sci Rep. 2021 Jan 12;11(1):667. doi: 10.1038/s41598-020-79648-6. PMID: 33436720; PMCID: PMC7804318.

  • Bae S, Karnon J, Crane G, et al. Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective. Cost Eff Resour Alloc. 2020;18:5. Published 2020 Feb 3. doi:10.1186/s12962-020-0202-7

  • Endo-Munoz L, Bennett TC, Topkas E, et al. Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma. Vet Comp Oncol. 2020;18(2):206-213. doi:10.1111/vco.12533

  • Fordham AM, Xie J, Gifford AJ, et al. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma [published online ahead of print, 2020 Jul 20]. Br J Cancer. 2020;10.1038/s41416-020-0996-2. doi:10.1038/s41416-020-0996-2

  • Rwandamuriye FX, Weston BJ, Johns TG, Lesterhuis WJ, Zemek RM. A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies. J Vis Exp. 2020 Jul 28;(161). doi: 10.3791/60882. PMID: 32804161.

  • Shin SJ, Dodd-Eaton EB, Peng G, et al. Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. Cancer Res. 2020;80(2):354-360. doi:10.1158/0008-5472.CAN-19-0728

  • Terry RL, Meyran D, Ziegler DS, Haber M, Ekert PG, Trapani JA, Neeson PJ. Immune profiling of pediatric solid tumors. J Clin Invest. 2020 Jul 1;130(7):3391-3402. doi: 10.1172/JCI137181. PMID: 32538896; PMCID: PMC7324195.

  • Vargas, A.C., Kurek, C., Bonar, F., Maclean, F., Qiu, M.R., Boyle, R.A., Brookwell, R., & Gill, A.J. (2020). A “Double-Hit” Translocation Sarcoma—First Report of the Co-occurrence of EWSR1-FLI1 and MTMR2-NTRK2 Fusion in a Small Round Blue Cell Sarcoma. AJSP: Reviews & Reports, 25, 100 - 97.

  • Vargas AC, Maclean FM, Sioson L, Tran D, Bonar F, Mahar A, Cheah AL, Russell P, Grimison P, Richardson L, Gill AJ. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. PLoS One. 2020 Apr 15;15(4):e0222551. doi: 10.1371/journal.pone.0222551. PMID: 32294103; PMCID: PMC7159201.

  • Young R, Snow H, Hendry S, et al. Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a single-centre study. ANZ J Surg. 2020;90(4):497-502. doi:10.1111/ans.15723

  • Zaborowski M, Vargas AC, Pulvers J, Clarkson A, de Guzman D, Sioson L, Maclean F, Chou A, Gill AJ. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases. Histopathology. 2020 Oct;77(4):588-600. doi: 10.1111/his.14190. Epub 2020 Sep 12. PMID: 32559341.

  • Dirksen U, Brennan B, Le Deley MC, et al. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019;37(34):3192-3202. doi:10.1200/JCO.19.00915

  • Judson I, Morden JP, Kilburn L, et al. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Oncol. 2019;20(7):1023-1034. doi:10.1016/S1470-2045(19)30215-3

  • Shekhar TM, Burvenich IJG, Harris MA, et al. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice. BMC Cancer. 2019;19(1):924. Published 2019 Sep 14. doi:10.1186/s12885-019-6103-5

  • Trahair T, Gifford A, Fordham A, et al. Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors. JCO Precis Oncol. 2019;3:1-11. doi:10.1200/PO.18.00297

  • White VM, Orme LM, Skaczkowski G, et al. Management of Sarcoma in Adolescents and Young Adults: An Australian Population-Based Study. J Adolesc Young Adult Oncol. 2019;8(3):272-280. doi:10.1089/jayao.2018.0136

  • Gelderblom H et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018;19:639-48.

  • Liu Z et al. Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood. Cancer Chemother Pharmacol. 2018. https://doi.org/10.1007/s00280-018-3683-8.

  • Mark A. Miles and Christine J. Hawkins. Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways.  Scientific Reports. 8(1):14421, 2018.

  • Rasmussen V et al. A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. Per Med. 2018;15:13-24.

  • Skaczkowski G et al. Do Australian adolescents’ and young adults’ experiences of cancer care influence their quality of life? Psychooncology. 2018;27:990-7.

  • Skaczkowski G et al. Factors influencing the provision of fertility counselling and impact on quality of life in adolescents and young adults with cancer. J Psychosoc Oncol. 2018;15:1-19.

  • Tan MTL et al. Patterns of care of superficial soft tissue sarcomas: it is not always just a lump. Asia Pac J Clin Oncol. 2018.

  • White V et al. Experiences of Care of Adolescents and Young Adults with Cancer in Australia. J Adolesc Young Adult Oncol. 2018;7:315-25.

  • Willis AM et al. Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk. J Genet Couns. 2018.

  • Xiaochun Wang, David Goldstein, Philip Crowe and Jia-Lin Yang. Anti-tumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines. International Journal.

  • Ballinger ML et al. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol. 2017;3:1634-9.

  • Ballinger ML, Best A, Mai PL et al, Surveillance in Li Fraumeni Syndrome using whole body magnetic resonance imaging: A Meta analysis, JAMA Oncol. 2017 Aug 3. doi: 10.1001/jamaoncol.2017.1968. [Epub ahead of print] PMID: 28772291.

  • Ballinger ML, Ferris NJ, Moodie K et al, Surveillance in germline TP53 mutation carriers utilizing whole body magnetic resonance imaging, JAMA Oncol. 2017 Aug 3. doi: 10.1001/jamaoncol.2017.1355. [Epub ahead of print] No abstract available. PMID: 28772290.

  • Leroy B et al. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res. 2017;77:1250-60.

  • Lewin J et al. Variations of Surveillance Practice for Patients with Bone Sarcoma: A Survey of Australian Sarcoma Clinicians. Sarcoma. 2017;2017.

  • McBride, K. A., Ballinger, M. L., Schlub, T. E., Young, M. A., Tattersall, M. H. N., Kirk, J., . . . Mitchell, G. (2017). Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Fam Cancer, 16(3), 423-432. doi:10.1007.

  • Peng G et al. Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO. Cancer Epidemiol Biomarkers Prev. 2017;26:837-844.

  • Tap WD et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1089-103.

  • Bae S et al. Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services. Clin Sarcoma Res. 2016;6:11.

  • Ballinger ML et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016;17:1261-71.

  • Burgess A et al. Clinical Overview of MDM2/X-Targeted Therapies. Front Oncol. 2016;6:7.

  • McBride KA, Hallowell N, Tattersall MH, Kirk J, Ballinger ML, Thomas DM, Mitchell G, Young MA. 'Timing and context: important considerations in the return of genetic results to research participants.' J Community Genet. 2016 Jan;7(1):11-20. doi: 10.1007/s.

  • McBride, K. A., Hallowell, N., Tattersall, M. H., Kirk, J., Ballinger, M. L., Thomas, D. M., . . . Young, M. A. (2016). Timing and context: important considerations in the return of genetic results to research participants. J Community Genet, 7(1), 11-20.

  • McBride, K. A., Schlub, T. E., Ballinger, M. L., Thomas, D. M., & Tattersall, M. H. (2016). International survey of awareness of genetic risk in the clinical sarcoma community. Asia Pac J Clin Oncol, 12(2), 133-142. doi:10.1111/ajco.12457.

  • McCaughan GJ et al. Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. J Hematol Oncol. 2016;9:48.

  • Tanmay M. Shekhar, Mark A. Miles, Ankita Gupte, Scott Taylor, Brianna Tascone, Carl R. Walkley and Christine J. Hawkins, IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα, Oncotarget, Vol. 7, No. 23: 33866-33886.

  • Thomas DM et al. Diagnosis and Management of Hereditary Sarcoma. Recent Results Cancer Res. 2016;205:169-89.

  • Topkas, E, Cai, N, Cumming A, Saunders NA, Endo-Munoz L. Auranofin is a potent suppressor of osteosarcoma metastasis. Oncotarget 7:831-844, 2016.

  • WALIA MK, Ho PM, Taylor S, Ng AJ, Gupte A, Chalk AM, Zannettino AC, Martin TJ, Walkley CR. Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance. eLife. 2016 Apr 12;5. pii: e13446. doi:10.7554.

  • Xiaochun Wang, David Goldstein, Philip J. Crowe, Mark Yang, Kerryn Garrett, Nikolajs Zeps and Jia-Lin Yang. Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. Oncotarget (2016); 7(16):21496-215.

  • Ballinger ML, Mitchell G, Thomas DM. Surveillance recommendations for patients with germ-line TP53 mutations. Current Opinion in Oncology 2015, Vol 27 No 4 p332-337.

  • Broadhead ML, Lokmic Z, Tan ML, Stevenson A, Binns DS, Cullinane C, Hicks RJ, Choong PF, Myers DE. Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma. Frontiers in surgery 2 : 36(2015).

  • Gupte A et al. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res. 2015;21:3216-29.

  • Kate McBride; Nina Hallowell; Martin H.N. Tattersall ; Judy Kirk ; Mandy L. Ballinger; David M. Thomas; Gillian Mitchell & Mary-Anne Young. Timing and Context: Important considerations in the return of genetic results to research participants. Journal of Community Genetics 2015, DOI 10.1007/s12687-015-0231-7.

  • McBride et al. An international survey of awareness of genetic risk in the clinical sarcoma community, 2015 Asia Pacific Journal of Clincal Oncology.

  • Mirabello L et al. A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov. 2015;5:920-31.

  • Pishas KI, Adwal A, Neuhaus SJ, Clayer MT, Farshid G, Staudacher AH & Callen DF. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Sci Rep. 2015 Jun 22;5:11465.

  • Sampson JN et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. 2015;107.

  • Thomas DM, Ballinger ML. Etiologic, environmental and inherited risk factors in sarcomas. J Surg Oncol. 2015 Apr;111(5):490-5. doi: 10.1002/jso.23809. Epub 2014 Oct 21.

  • Thomas DM, James PA, Ballinger ML. Personal View - Clinical implications of genomics for cancer risk genetics. Lancet Oncology 2015; 16:e303-08.

  • Chawla SP et al. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014;32:3299-306.

  • Judson I et al. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res. 2014;20:3603-12.

  • Lewin J et al. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer. 2014;111:2254-61.

  • McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A. Mitchell, G. (2014). Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nature Reviews Clinical Oncology, 11(5), 260-271. doi:10.1038/nrc.

  • Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW et al. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Research. 2014 Feb 1;74(3):921-31.

  • Cain JE, McCaw A, Jayasekara S, Rossello FJ, Marini KD, Irving AT, Kansara M, Thomas DM, Ashley DM, Watkins DN.  Sustained Treatment With Low Dose Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma, 2013.

  • Collins M et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol. 2013;31:2303-12.

  • Mitchell G et al. High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One. 2013;8.

  • Pishas KI, Neuhaus SJ, Clayer MT, Adwal A, Brown MP, Evdokiou A, et al. Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to Drozitumab therapy. Oncology Reports. 2013 Jul;30(1):471-7.

  • Savage et al. Genome-wide association study identifies novel loci associated with osteosarcoma, 2013 Nature Genetics Vol 45 No 7, p799.

  • Young, M-A, Herlihy A, Thomas D, Ballinger M, Tucker K, Neuhaus S, Halliday J. 'The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research' Clinical Sarcoma Res. 2013 Jul 30;3(1):11.

  • Downing et al. An increased incidence of Hodgkin’s lymphoma in patients with adult-onset sarcoma, Clinical Sarcoma Research 2012, 2:1
  • Broadhead, Matthew L and Clark, Jonathan C. M and Dass, Crispin R and Choong, Peter F. M and Myers, Damian E (2011) Therapeutic targeting of osteoclast function and pathways. Expert Opinion on Therapeutic Targets, 15 (2). pp. 169-181. ISSN 1472-8222.
  • Choong, Peter F. M and Broadhead, Matthew L and Clark, Jonathan C. M and Myers, Damian E and Dass, Crispin R (2011) The molecular pathogenesis of osteosarcoma: A review. Sarcoma, 2011. pp. 1-12. ISSN 1357-714X.
  • Neilsen PM, Pishas KI, Callen DF and Thomas DM. Targeting the p53 pathway in Ewing Sarcoma. Sarcoma. 2011:746939.
  • Pishas KI, Al-Ejeh F, Zinonos I, Brown MP, Evdokiou A, Callen DF and Neilsen PM. Nutlin-3a is a potential therapeutic for Ewing Sarcoma. Clinical Cancer Research. 2011; 17(3):494-504.

Information accurate as of 28 August 2023